Prostate Cancer
Clinical research activity is centered on intermediate-risk localized prostate cancer, with interest in treatment strategies designed to balance cancer control and preservation of function.
- Oncologic control
- Localized prostate cancer
- Intermediate-risk disease
The sponsor’s trial portfolio reflects a focused interest in therapies for men with organ-confined prostate malignancy managed within a hospital-based care setting in Paris.
Focal Ablation Therapy
Research includes high-intensity focused ultrasound as a prostate-directed focal treatment, with attention to selective tissue ablation in a localized disease context.
- HIFU hemiablation
- Focal prostate treatment
- Organ-preserving therapy
This area highlights therapeutic interest in non-surgical approaches for prostate tumor management.
Hormonal Therapy in Prostate Cancer
The sponsor also studies androgen deprivation therapy in combination with local treatment, reflecting interest in hormonal modulation as part of prostate cancer care.
- Short-term ADT
- Combined modality treatment
- Prostate-specific endocrine management
Therapeutic activity in this domain is linked to optimizing disease control in men with localized prostate cancer.
Functional Outcomes and Morbidity
Clinical research also addresses treatment-related effects on erectile function, ejaculatory function, and urinary continence, alongside broader morbidity assessment.
- Sexual function
- Urinary continence
- Treatment-related morbidity
These outcomes indicate an interest in the functional impact of prostate-directed therapy within routine clinical care.
